Abnormal Presentation of Hypoxic Ischemic Encephalopathy Attributed to Polysubstance Exposure (original) (raw)
2019, American Journal of Case Reports
Congenital defects/diseases Background: With the increasing prevalence of substance use in pregnancy, the rates of neonatal abstinence syndrome (NAS) are dramatically increasing. There is little information on the use of multiple substances in adults, even less so of polysubstance abuse during pregnancy and the consequences for the fetus as well as the mother. Case Report: A newborn male born at 35 weeks presented post-delivery with hips bilaterally dislocated and hyperflexed. The patient's legs fully extended and their shoulders were bilaterally mid-flexed with arms fully extended. This neonate was also reported to have bilateral hearing and vision loss as well as NAS symptoms of high-pitched crying and respiratory distress. During pregnancy the mother in this case study admitted to using buprenorphine, benzodiazepines, gabapentin, and heroin. The consequences of using this combination has not been well studied in pregnancy. Conclusions: The presented case had severe complications, likely due to maternal polysubstance use and poor prenatal care in pregnancy. Clonidine was used to control the NAS symptoms, ranitidine was used to treat the gastroesophageal reflux, and glycopyrronium bromide was used for the neonate's excessive secretions. After delivery, the patient was placed on a nasal noninvasive cannula for respiratory distress and was transferred to a different hospital for treatment of the more serious comorbid conditions.
Related papers
Neonatal Abstinence Syndrome Due to Opioid Abuse in Pregnancy
Gynecology Obstetrics & Reproductive Medicine
Opioid abuse during pregnancy is increasing in women of childbearing age in Turkey. The frequency of clinical signs of withdrawal in infants who exposed to heroin in utero are varying between 16-90%. Here, we present five newborn infants presenting with neonatal abstinence syndrome who were hospitalized in Neonatal Intensive Care Unit of Mersin Maternity and Children's Hospital. All of the five infants were symptomatic including irritability, tremors, high-pitched cry, excessive sucking and seizure. Hyperirritability was the predominant sign. Seizure was observed two of the five infants which clinically presented between 1 st-5 th day of life and was controlled with phenobarbital. We have experienced seizure due to withdrawal of opioid more than the past reports and we thought that interrupting breastfeeding may facilitate seizure. Breastfeeding may slow down the decrease of opioid level in blood and may reduce the symptoms. In conclusion, opioid abuse in pregnancy is a growing sociological problem in Turkey and a protocol for management is required for neonatologists.
Symptomology Associated with in Utero Exposures to Polysubstance in an Appalachian Population
Marshall Journal of Medicine, 2019
Neonatal abstinence syndrome (NAS) is seen at a very high rate at our institution in Huntington, West Virginia, and the majority of exposures are polysubstance in nature. Polysubstance can have different meanings for different regions. At our institution, polysubstance is any combination of opioids, gabapentin, methamphetamine, cocaine, marijuana, benzodiazepines, nicotine or other neuroactive substances with three to four substances being the norm. Rapidly changing combinations of drug use and the lack of literature creates a difficult situation for clinicians who are often reliant on treatment recommendations that lack references or conclusive data supporting the clinical approaches. Elucidating withdrawal symptoms consistent with in utero exposures to particular drug combinations is difficult. Many substances induce similar withdrawal symptoms in neonates and the vast majority of cases present as polysubstance exposure. Standard methodology often leads to a research approach which isolates populations and substance of exposure to determine the individual effects on the neonate. In some drug combinations, like opioid and gabapentin exposure, the substances in concert create symptoms and complications that are not observed with either drug alone. The history of responses to substance use epidemics has been to handle each drug as a separate disease process; this is no longer a viable option. The following is a review of the literature available discussing individual substance withdrawal characteristics in neonates combined with the clinical insight gained at our hospital from treating such high rates of complex polysubstance exposure.
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
2010
Methadone, a full mu-opioid agonist, is the recommended treatment for opioid dependence during pregnancy. However, prenatal exposure to methadone is associated with a neonatal abstinence syndrome (NAS) characterized by central nervous system hyperirritability and autonomic nervous system dysfunction, which often requires medication and extended hospitalization. Buprenorphine, a partial mu-opioid agonist, is an alternative treatment for opioid dependence but has not been extensively studied in pregnancy.
Buprenorphine for the Neonatal Abstinence Syndrome
New England Journal of Medicine, 2017
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure-response relationships and facilitate dose optimization. NEONATAL ABSTINENCE SYNDROME The placental transfer of drugs from the mother to the fetus is well described. The developmental kinetics of drug permeability at the fetal "blood-brain barrier" in humans is not fully defined, but is clearly immature early in pregnancy. 1 Many prescribed medications or drugs of abuse can impact postnatal outcomes, particularly with chronic use during pregnancy. Some substances cause neonatal symptomatology that is a direct effect of maternal transfer of the xenobiotic to the neonate. This is characteristic of a toxidrome. For example, intrauterine cocaine exposure is associated with tremors, high-pitched cry, and autonomic instability in the infant that is self-limited and improves as the drug is cleared from the system. 2 Other psychoactive agents are associated with symptoms that emerge as the drug concentration falls within the neonate, indicating a withdrawal syndrome. Opioids, serotonin reuptake inhibitors, 3 nicotine, 4 and antipsychotics 5 all can cause withdrawal or adaptation symptoms. The term "neonatal abstinence syndrome" is nonspecific. While the bulk of morbidity and symptoms are due to withdrawal from opioids, concomitant maternal use of other drugs associated with withdrawal symptoms is common. These exposures typically will worsen NAS symptoms and duration, but exposures are difficult to quantify in practice and ultimately do not impact management decisions. Others, including the US Food and Drug Administration (FDA), advocate the use of the term "neonatal opioid withdrawal syndrome" (NOWS) to more specifically link symptoms to opioid exposure. 6 For the purposes of this review, the more commonly and general term NAS will be used to implicitly describe withdrawal symptoms driven primarily by in utero opioid exposure.
Neonatal Effects of Substance Abuse during Pregnancy
Iranian Journal of Neonatology IJN, 2016
Drug abuse in pregnancy is not uncommon, and the use of illicit opioids during pregnancy is associated with an increased risk of adverse outcomes. The aim of the study was to assess neonatal outcome of pregnancy with maternal addiction. Materials and Methods: In this cohort study we assessed 100 pregnant women 15 -49 years old. To identify drug exposure was used self- questionnaire (Self-Report). Data on pregnancies complicated by illicit drug abuse (n = 50) were collected during a 2-year period (2014 - 2016) at Hospitals affiliated to Mashhad University of medical sciences. Data on the type of drug, course of gestation and labor, and on neonatal complications outcome were considered. Medical records on all non-dependence pregnancies during the study period were used as a non-exposed group (n = 50).To control possible confounding factor was used of multiple logistic regression model. Results: our results showed The risk of various congenital anomalies was 5-fold in the group of ch...
Clinical presentation and management of neonatal abstinence syndrome: an update
Research and Reports in Neonatology, 2014
Exposure to prescription medications and illicit drug use during pregnancy has been associated with neonatal abstinence syndrome. The clinical presentation consists of neurological respiratory, gastrointestinal, and vasomotor disturbances. All infants require observation and supportive care to ensure appropriate adaptation and growth in the newborn period. A smaller percentage may also require additional pharmacotherapy, depending on the specific gestational substance exposure. Women should be counseled antenatally about the possible neonatal effects, and mother-baby dyad care should be implemented for this particular patient population.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.